Surface-enhanced Raman spectroscopy of serum predicts sensitivity to docetaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer

Jianian Hu; Xiaoguang Shao; Chenfei Chi; Yinjie Zhu; Zhixiang Xin; Jianjun Sha; Baijun Dong; Jiahua Pan; Wei Xue

doi:10.1142/s1793545821410066

[1] R. L. Siegel, K. D. Miller, A. Jemal, "Cancer statistics, 2020," CA Cancer J. Clin. 70, 7–30 (2020).

[2] W. P. Harris, E. A. Mostaghel, P. S. Nelson, B. Montgomery, "Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion," Nat. Clin. Pract. Urol. 6, 76–85 (2009).

[3] NCCN clinical practice guidelines in Oncology: Prostate Cancer (Version1.2016).

[4] D. P. Petrylak, C. M. Tangen, M. H. Hussain, P. N. Lara Jr. J. A. Jones, M. E. Taplin et al., "Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer," N. Engl. J. Med. 351, 1513–1520 (2004).

[5] I. F. Tannock, R. de Wit, W. R. Berry, J. Horti, A. Pluzanska, K. N. Chi et al., "Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer," N. Engl. J. Med. 351, 1502–1512 (2004).

[6] A. J. Armstrong, I. F. Tannock, R. De Wit, D. J. George, M. Eisenberger, S. Halabi, "The development of risk groups in men with metastatic castration- resistantprostate cancer based on risk factors for PSA decline and survival," Eur. J. Cancer 46 (3), 517–525 (2010).

[7] R. J. van Soest, E. S. de Morree, L. Shen et al., "Initial biopsy Gleason score as a predictive marker for survival benefit in patients with castration-resistant prostate cancer treated with docetaxel: Data from the TAX327 study," Eur. Urol. 66, 330–336 (2014).

[8] J. S. de Bono, H. I. Scher, R. B. Montgomery et al., "Circulating tumor cellspredict survival benefit from treatment in metastatic castration resistant prostate cancer," Clin. Cancer Res. 14, 6302–6309 (2008).

[9] I. G. Jeong, J. H. Lim, S. S. Hwang et al., "Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy," Prostate Int. 1 (2), 69–75 (2013).

[10] G. F. Wang, R. J. Lipert, M. Jain et al., "Detection of the potential pancreatic cancer marker MUC4 in serum using surface-enhanced Raman scattering," Anal. Chem. 83(7), 2554–2561 (2011).

[11] C. Na, R. Ming, S. Xiaoguang et al., "Surface-enhanced Raman spectroscopy of serum accurately detects prostate cancer in patients with prostatespeci fic antigen levels of 410 ng/mL," Int. J. Nanomed. 12, 5399–5407 (2017).

[12] S. Cervo, E. Mansutti, G. Del Mistro et al., "SERS analysis of serum for detection of early and locally advanced breast cancer," Anal Bioanal. Chem. 407 (24), 7503–7509 (2015).

[13] J. Wang, D. Lin, J. Q. Lin et al., "Label-free detection of serum proteins using surface-enhanced Raman spectroscopy for colorectal cancer screening," J. Biomed. Opt. 19(8), 087003 (2014).

[14] S. Li, L. Li, Q. Zeng et al., "Characterization and noninvasive diagnosis of bladder cancer with serum surface enhanced Raman spectroscopy and genetic algorithms," Sci. Rep. 5, 9582 (2015).

[15] X. Lili, Y. Bing, L. Yi et al., "Surface-enhanced Raman spectroscopy of blood serum based on gold nanoparticles for tumor stages detection and histologic grades classification of oral squamous cell carcinoma," Int. J. Nanomed. 13, 4977–4986 (2018).

[16] J. Pan, X. Shao, Y. Zhu et al., "Surface-enhanced Raman spectroscopy before radical prostatectomy predicts biochemical recurrence better than CAPRA-S," Int. J. Nanomed. 14, 431–440 (2019).

[17] J. L. Gonzalez-Solís, J. C. Martínez-Espinosa, J. M. Salgado-Roman et al., "Monitoring of chemotherapy leukemia treatment using Raman spectroscopy and principal component analysis," Lasers Med. Sci. 29(3), 1241–1249 (2014).

[18] H. I. Scher, M. J. Morris,W. M. Stadler et al., "Trial design and objectives for castration-resistant Prostate Cancer: Updated recommendations from the Prostate Cancer clinical trials working group 3," Jo. Clin. Oncol. 34(12), 1402 (2016).

[19] P. C. Lee and D. Melsel, "Absorption and surfaceenhanced Raman of dyes on silver and gold sols," J. Phys. Chem. 86(17), 3391–3395 (1982).

[20] X. Shao, J. Pan, Y. Wang et al., "Evaluation of expressed prostatic secretion and serum using surface- enhanced Raman spectroscopy for the noninvasive detection of prostate cancer, a preliminary study," Nanomed. Nanotechnol. Biol. Med. 13(3), 1051–1059 (2017).

[21] S. Feng, W. Wang, I. T. Tai et al., "Label-free surface- enhanced Raman spectroscopy for detection of colorectal cancer and precursor lesions using blood plasma," Biomed. Opt. Exp. 6(9), 3494–3502 (2015).

[22] D. Lin, J. Pan, H. Huang et al., "Surface-enhanced Raman scattering for tumor stages detection in nasopharyngeal cancer," Sci. Rep. 4, 4751 (2014).

[23] Z. Movasaghi, S. Rehman, Dr.I. U. Rehman, "Raman spectroscopy of biological tissues," Appl. Spectrosc. Rev. 42(5), 493–541 (2007).

[24] A. J. Templeton, M. G. McNamara, B. Seruga et al., "Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and metaanalysis," J. Natl. Cancer Inst. 106, dju124 (2014).

[25] G. Galletti, A. Matov, H. Beltran et al., "ERG induces taxane resistance in castration-resistant prostate cancer," Nat. Commun. 5, 5548 (2014).

[26] W. Song, G. Y. Kwon, J. H. Kim et al., "Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer," Oncotarget 7(50), 83735–83743 (2017).

[27] M. Marin-Aguilera, J. Codony-Servat, O. Reig et al., "Epithelial-to mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer," Mol. Cancer Ther. 13, 1270–1284 (2014).

[28] O. Reig, M. Marin-Aguilera, G. Carrera et al., "TMPRSS2-ERG in blood and docetaxel resistance in metastatic castration-resistant prostate cancer," Eur. Urol. 70, 709–713 (2016).

[29] K. Kong, C. Kendall, N. Stone, I. Notingher, "Raman spectroscopy for medical diagnostics—From in-vitro biofluid assays to in-vivo cancer detection," Adv. Drug Deliv. Rev. 89, 121–134 (2015).

[30] P. S. Gonzalez, J. O'Prey, S. Cardaci et al., "Mannose impairs tumour growth and enhances chemotherapy," Nature, 563, 719–723 (2018), doi: 10.1038/s41586-018-0729-3.